TCTMD’s Top 10 Most Popular Stories for June 2018
Valve interventions dominated the list, but leading were a feature on the defensibility of routine transfemoral PCI and andexanet alfa’s approval.
Topping the most popular list for June 2018 was a feature on the potential legal pitfalls of sticking with a routine transfemoral PCI practice, with the FDA approval of andexanet alfa coming a close second. Dominating the rest of the lineup was transcatheter valve news, including stories from the 2018 Structural Heart Disease Summit, and the sad news of Jack Tu’s death.
Most operators reject the idea that routine transfemoral PCI could be deemed malpractice, but also agree: radial needs a prominent role.
The agent is the second antidote approved for the NOACs, joining idarucizumab, dabigatran’s reversal agent.
After graduating from medical school at age 23, he built a legacy of professionalism, kindness, and dedication to improving quality of care.
In contrast to the American recommendations, traditional classifications are maintained and treatment targets are not as aggressive.
CMS is set to ponder minimum volume requirements as part of the national coverage decision, but some docs worry volume is not the whole story.
Getting a good seal is the chief concern, and while cases are uncommon now, experts expect more as TAVR moves into younger, lower-risk patients.
As COAPT and MITRA-FR crest the horizon, surgeons and cardiologists alike have plenty of opinions about the future of repair in severe MR.
The largest series to date of patients treated with MitraClip in the tricuspid position appears in a special journal issue focused on valve interventions.
Four papers in JAMA Cardiology tackle the issues affecting women who are thinking about joining or who have already joined the male-dominated field.
One operator said the occlusion rate at 24 hours remains too high, suggesting more work is needed to reduce this complication after transradial access.